Determining the Effect of Home BLOOD Glucose Monitoring on HBA1C in Patients With Type 2 Diabetes Using Smartphone Application

NCT07647523 | Completed

• 1 other identifier: 2019/29-25
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the effectiveness of a web and mobile-based clinical decision support and monitoring system (1B4T mobile application) on blood glucose control, medication adherence, quality of life, and self-management in patients with poorly controlled Type 2 Diabetes Mellitus. This open-label, parallel-group, randomized controlled trial was conducted with 100 type 2 diabetes patients registered at primary care family health centers in Izmir, Turkey. Participants were randomly assigned to either the intervention group (n=50) or the control group (n=50).

• Intervention Group: Participants installed the 1B4T mobile application on their smartphones, created personal accounts, and recorded their home blood glucose measurements through the app for 3 months. The app allowed patients to track their previous data and view a 10-day blood glucose prediction without directing any treatment changes.
• Control Group: Participants continued with their routine healthcare follow-ups and standard controls. At baseline and at the 3-month follow-up, fasting plasma glucose and HbA1c levels were measured for all participants. Additionally, sociodemographic characteristics, medication adherence (Modified Morisky Medication Adherence Scale), quality of life (WHOQOL-BREF-TR), and diabetes self-management (Diabetes Self-Management Questionnaire - DSMQ) were evaluated to assess the clinical and behavioral outcomes of the mobile health intervention.

Conditions

Diabetes Mellitus, Type 2

Outcome Measures

Primary Outcomes (1)

• Change in Hemoglobin A1c (HbA1c)

  The mean change in Hemoglobin A1c (HbA1c) levels from baseline to the end of the 3rd month will be evaluated to assess glycemic control. HbA1c is measured as a percentage (%) to reflect the average blood glucose levels over the past 3 months.

  Baseline and 3 months

Secondary Outcomes (1)

• Change in Fasting Plasma Glucose (FPG)

  Baseline and 3 months

Study Arms (2)

Control

NO INTERVENTION

Intervention

EXPERIMENTAL

Participants in this arm will use the 1B4T mobile application for home blood glucose monitoring over a 3-month period. Each participant will receive a unique username and password to access their private profile on the smartphone application. Patients will record their self-measured blood glucose levels directly into the app. The digital platform allows them to monitor their historical data and view a 10-day blood glucose prediction generated by the system's clinical decision support software. The application functions strictly as a tracking and monitoring tool and does not direct, alter, or modify any medical treatment. Follow-up clinical and behavioral assessments (HbA1c, fasting plasma glucose, medication adherence, quality of life, and self-management scales) will be conducted at the end of the 3rd month.

Other: Smartphone Application for Blood Glucose Monitoring

Interventions

Smartphone Application for Blood Glucose Monitoring OTHER

The intervention involves the use of the "1B4T" mobile application, a web and mobile-based clinical decision support and monitoring system developed with TUBITAK funding. Participants in the intervention group will receive a personalized username and password to log into their secure profiles on their smartphones. Patients are instructed to self-measure and log their blood glucose levels directly into the application over a 3-month period. Based on the user-entered data, the application generates and displays a 10-day blood glucose prediction, allowing patients to track their historical trends. The mobile software functions strictly as a data logging and monitoring platform for home self-management and does not provide any clinical guidance, treatment modification, or medication dosage adjustments.

Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Volunteering to participate in the study.
• Having poorly controlled Type 2 Diabetes Mellitus (HbA1c \> 7%).
• Using a smartphone.
• Being over 18 years of age.
• Ability to speak and understand Turkish.
• Being at least a primary school graduate.
• Having full orientation to person, place, and time.

You may not qualify if:

• Having participated in any diabetes-related study within the last 3 months.
• Inability to attend regular clinical follow-up visits.
• Having severe visual or hearing impairments.

Sponsors & Collaborators

• Dokuz Eylul University: lead

Study Sites (1)

Dokuz Eylul University

Izmir, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Blood Glucose

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Glucose; Hexoses; Monosaccharides; Sugars; Carbohydrates

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Asistant Professor

Study Record Dates

• First Submitted: June 9, 2026
• First Posted: June 15, 2026
• Study Start: February 1, 2021
• Primary Completion: August 1, 2021
• Study Completion: September 1, 2021
• Last Updated: June 15, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)